1. Inhibitory Antibodies

Inhibitory Antibodies

Inhibitory Antibodies (13):

Cat. No. Product Name Purity Concentration
  • HY-P9903
    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P9905
    Cetuximab >99.0%
    Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with antitumor activity.
  • HY-P9912
    Pertuzumab, a humanized monoclonal antibody, is a EGFR2 dimerization inhibitor for the treatment of metastatic EGFR2-positive breast cancer.
  • HY-P9910
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
  • HY-P9911
    Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
  • HY-P9904
    Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P9907
    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2.
  • HY-P9908
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). MW:150 kDa.
  • HY-P9913
    Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
  • HY-P9902
    Lambrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P9901
    Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells. 
  • HY-P9909
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
  • HY-P9906
    Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity. MW : 149 kDa.